---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-122772"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:21:19.409132+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# EyePoint Q3 net loss $29.4M; positive DURAVYU interim data, $161M equity financing

## Summary
- Q3 net loss $29.4M ($0.54 per share) vs. $12.6M loss a year ago; revenue $10.5M down from $15.2M.
- Interim Phase 2 VERONA data: DURAVYU 2.7mg showed +8.9 BCVA letters and -68 μm CST improvement at 16 weeks vs. aflibercept.
- First patient dosed in Phase 3 LUGANO trial for wet AMD; second Phase 3 LUCIA first patient dosing expected by end of 2024.
- Completed $161M oversubscribed public equity offering at $11.00/share; cash runway extended into 2027.
- Opened 40,000 sq ft cGMP commercial manufacturing facility in Northbridge, MA for DURAVYU.

## SEC filing metadata
- accession: 0000950170-24-122772
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000095017024122772/0000950170-24-122772-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000095017024122772/eypt-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-122772
- JSON: https://secwatch.observer/filing/0000950170-24-122772.json
- Plain text: https://secwatch.observer/filing/0000950170-24-122772.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.